ESR1 and breast cancer: We identified a unique transcriptome associated with the ERα Y537S mutation at shared regulatory binding sites of ERα and PR, including near IRS1. Our results suggest that inhibition of insulin receptor substrate-1 (IRS1) may restore therapeutic sensitivity to patients with ET-resistant breast cancer.